Abstract
SUMMARYBenzodiazepines have attracted controversy from shortly after their introduction. They have been subject to periodic calls for their use to be re-evaluated on the basis that their risks have been overstated and their benefits underappreciated. Claims made in recent editorials from the International Task Force on Benzodiazepines in support of their wider use are critiqued in this issue. I examine here whether there is a case to change the conclusions of previous reconsiderations of the question.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference10 articles.
1. Office for National Statistics (2022) Drugs Related to Drug Poisoning in England and Wales: 2021 Registrations. ONS (www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2021registrations).
2. Stigmatization of Benzodiazepines: Pharmacologic and Nonpharmacologic Contributions
3. The devil is in the detail: a critique of nine editorials published by the International Task Force on Benzodiazepines;Brandt;BJPsych Advances,2022
4. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies
5. Why benzodiazepines are not going away